Therapeutic Classification: antineoplastics
Pharmacologic Classification: alkylating agents
Absorption: Rapidly converted to MTIC, the active metabolite.
Distribution: Unknown.
Metabolism/Excretion: Further metabolism results in the formation of methylhydrazine, which is responsible for most activity.
Half-life: 1.8 hr.
CNS: SEIZURES, fatigue, headache, abnormal coordination, anxiety, depression, dizziness, drowsiness, mental status changes, weakness.
EENT: abnormal vision, diplopia.
Resp: cough.
CV: peripheral edema.
GI: HEPATOTOXICITY, nausea, vomiting, abdominal pain, anorexia, constipation, diarrhea, dysphagia.
Derm: pruritus, rash.
Endo: adrenal hypercorticism.
Hemat: leukopenia, thrombocytopenia, anemia.
Metab: ↑weight.
MS: abnormal gait, back pain.
Neuro: hemiparesis, myalgia.
Misc: breast pain (women), fever, injection site reactions, pain at injection site, secondary malignancies (rare).
1.5 x 109/L, a platelet count of 
Grade 1 (except for alopecia, nausea and vomiting). Obtain CBC weekly. If ANC is